Drug Type Recombinant protein |
Synonyms- |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Prolactin receptor modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 1 | US | 01 Feb 2016 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 1 | US | 01 Feb 2016 | |
Recurrent ovarian cancer | Phase 1 | US | 01 Feb 2016 | |
Breast Cancer | Phase 1 | - | - | |
Prostatic Cancer | Phase 1 | - | - |